MedTrace Logo

Philippine Trial to Determine Efficacy and Safety of Favipiravir for COVID-19

NCT05014373 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2021-08-20

No results posted yet for this study

Summary

This is an open label randomized controlled clinical trial which was designed to confirm the potential efficacy and safety of favipiravir in the management of patients with mild to moderate COVID-19 compared to best supportive care.

Conditions

  • Covid19

Interventions

COMBINATION_PRODUCT

Favipiravir + Standard of Care

1800 mg twice daily for one day, followed by 800mg (4 tablets) twice daily Plus Standard of Care

PROCEDURE

Standard of Care

Best supportive care includes Standard treatment included oral or intravenous rehydration, electrolyte correction, antipyretics, analgesics, antibiotics and antiemetic drugs \& the medication any patient is on due to any concomitant diseases.

Sponsors & Collaborators

  • Department of Health, Philippines

    collaborator OTHER_GOV

  • University of the Philippines

    lead OTHER

Principal Investigators

  • Regina. Berba., MD · Philippine General Hospital, Manila Philippines

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-12
Primary Completion
2021-08-31
Completion
2021-08-31

Countries

  • Philippines

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05014373 on ClinicalTrials.gov